Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2024 / Oct / Gestational Diabetes Mellitus Screening Failures
Screening and monitoring Quality assurance and quality control

Gestational Diabetes Mellitus Screening Failures

Diagnoses could be missed when pregnant patients are screened with the casual blood glucose test

By Helen Bristow 10/08/2024 News 1 min read

Share

Japanese researchers investigating screening tools for gestational diabetes mellitus (GDM) have discovered that the casual blood glucose test (CBG) is less reliable than the 50-g glucose challenge test (GCT).

Credit: Adobe Stock (Edited)

The study, published in the Journal of Diabetes Investigation, included 763 pregnant women who underwent both the CBG measurement and the 50-g GCT at 24–28 weeks of gestation. Those who had a blood glucose level ≥140 mg/dL one hour after the GCT were subsequently tested using the 75-g oral glucose tolerance test (OGTT) to diagnose GDM. Overall, 240 women required further testing, with 97 (40.4%) being diagnosed with GDM .

The key finding was that using CBG levels alone, with a threshold of ≥100 mg/dL, would have failed to identify 71.7% of GDM cases that were detected using the GCT. Specifically, 71 out of 99 women who were diagnosed with GDM through the GCT had CBG levels below 100 mg/dL, underscoring the limitations of relying solely on CBG as a screening measure. The study also reported that CBG and GCT results were inconsistent in 38 percent of the cases.

In terms of clinical characteristics, women with GDM or overt diabetes mellitus had higher maternal age, body mass index before pregnancy, and were more likely to have conceived through assisted reproductive technology compared with those without GDM. However, contrary to common expectations, the study noted a lower incidence of multiple pregnancies in the GDM group, though the reasons for this remain unclear.

This study highlights the importance of appropriate screening strategies to prevent missed diagnoses of GDM, which can have long-term health consequences for both mothers and their infants. The authors conclude that, though CBG measurements are less resource-intensive and easier to administer than the GCT, they underestimate the prevalence of GDM. They recommend the use of the 50-g GCT as a more effective screening tool, particularly in regions where CBG is commonly used. Future prospective studies are planned to evaluate the combined use of CBG and the GCT to improve the sensitivity of GDM screening.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

About the Author(s)

Helen Bristow

Combining my dual backgrounds in science and communications to bring you compelling content in your speciality.

More Articles by Helen Bristow

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Flexible Solutions With FlexVUE
Screening and monitoring
Flexible Solutions With FlexVUE

December 29, 2021

1 min read

Quickly customize your immune panels with Ultivue’s new innovation

What’s New in Infectious Disease? (December 2021)
Screening and monitoring
What’s New in Infectious Disease?

December 23, 2021

1 min read

The latest research and news on COVID-19 and the infectious disease landscape

A Pig In a Poke
Screening and monitoring
A Pig In a Poke

October 21, 2016

1 min read

When importing livestock for food or breeding, European countries may inadvertently open their borders to superbugs as well

Sneaky Superbugs
Screening and monitoring
Sneaky Superbugs

October 21, 2016

1 min read

Norway’s strict LA-MRSA transmission measures prevent the import of almost all live pigs – but the bacteria have found a new way in

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.